Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma
NCT04555577
Recruiting
This phase I trial investigates the side effects and best dose of Peposertib, and to see how well it works in combination with radiation therapy in treating patients with newly diagnosed MGMT unmethylated glioblastoma or gliosarcoma. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Peposertib may further stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as temozolomide, work in different ways to stop th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Glioblastoma, Gliosarcoma
Register for Updates
Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma
NCT05236036
Recruiting
This phase I/Ib trial tests the safety, side effects, and best dose of mycophenolate mofetil in combination with temozolomide and/or radiation therapy (standard of care) in treating patients with glioblastoma. Mycophenolate mofetil is an immunosuppressant drug that is typically used to prevent organ rejection in transplant recipients. However, mycophenolate mofetil may also help chemotherapy with temozolomide work better by making tumor cells more sensitive to the drug. The purpose of this trial... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: Northwestern University, Chicago, Illinois
Conditions: Astrocytoma, Glioblastoma, Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma, Recurrent Glioblastoma
Register for Updates
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
NCT05503797
Recruiting
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors harboring BRAF fusions, or in participants with rare BRAF V600-mutated solid tumors, melanoma, thyroid, or recurrent primary CNS tumors.
Gender:
ALL
Ages:
10 years and above
Trial Updated:
05/13/2025
Locations: UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California +55 locations
Conditions: Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors, Melanoma BRAF V600E/K Mutated, Thyroid Cancer
Register for Updates
A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT05785767
Recruiting
This study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab (also called REGN2810), individually called a "study drug" or collectively called "study drugs". The study is focused on patients who have advanced non-small cell lung cancer (NSCLC). The aim of the study is to see how effective the combination of fianlimab and cemiplimab is in treating advanced NSCLC, in comparison with cemiplimab by itself. The study is looking... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: Arizona Clinical Research Center, Tucson, Arizona +110 locations
Conditions: Advanced Non-Small Cell Lung Cancer
Register for Updates
PRP Injections for Genitourinary Syndrome of Menopause
NCT06028009
Recruiting
Platelet-rich plasma (PRP) is autologous blood which has been centrifuged to separate the supernatant resulting in a solution with high concentration of platelets. Injection of PRP stimulates cell growth and can has been proven safe and effective for uses in orthopedics, dermatology, and gynecology. Despite the relative paucity of data, the use of PRP as a therapy for sexual dysfunction and genitourinary symptoms in the setting of menopause has been patented as the O-Shot and V-Shot. This is a s... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: MedStar Lafayette Medical Centre, Washington, District of Columbia
Conditions: PRP, Sexual Function Disturbances, Genitourinary Syndrome of Menopause, Postmenopausal Symptoms, Vaginal Atrophy
Register for Updates
CAPABLE Transplant
NCT06326905
Recruiting
The purpose of this mixed methods study is to adapt CAPABLE as CAPABLE Transplant to accomplish two things: 1) To resolve barriers to being classified as active on the Kidney Transplant (KT) waitlist, 2) as a surgical prehabilitation intervention targeting the pre-frail/ frail KT waitlist population. It consists of two phases- an open label pilot and a randomized waitlist control trial, and 3) pilot test the feasibility and acceptability for CAPABLE Transplant in symptom and waitlist specific me... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: Johns Hopkins School of Nursing, Baltimore, Maryland
Conditions: Quality of Life, Depression, End Stage Renal Disease, Disability Physical
Register for Updates
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis
NCT06527404
Recruiting
The main objective of the study will be to evaluate the efficacy of rocatinlimab compared with placebo at week 24 on the patient-reported outcome (PRO) measure of pruritus and overall clinical assessment score (US only).
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/13/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +179 locations
Conditions: Prurigo Nodularis
Register for Updates
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
NCT06774963
Recruiting
This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts +8 locations
Conditions: Ovarian Cancer, Breast Cancer, Endometrial Cancer, Biliary Tract Cancer, Non-Small Cell Lung Cancer, Advanced or Metastatic Solid Tumors
Register for Updates
Pro-2-Cool Pivotal Trial II
NCT06929923
Recruiting
This study is being conducted to quantify the clinical safety and efficacy of head and neck cooling, using the Pro-2-Cool device, when applied after mTBI injury sustained by adolescents aged 12-21 years, participating in sporting activities.
Gender:
ALL
Ages:
Between 12 years and 21 years
Trial Updated:
05/13/2025
Locations: University of Michigan, Ann Arbor, Michigan +1 locations
Conditions: Mild Traumatic Brain Injury
Register for Updates
Influence of Obesity on Endogenous Oxalate Synthesis
NCT03704350
Recruiting
There is increasing evidence that obesity is associated with increased urinary oxalate excretion, an important risk factor for calcium oxalate stone formation. By the administration of a controlled low oxalate diet the investigators will estimate endogenous oxalate synthesis in both non-obese and obese non-kidney-stone forming adults. This study seeks to thusly increase the understanding of the relationships between obesity and endogenous oxalate synthesis to serve as a platform to develop novel... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
05/13/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Kidney Stone
Register for Updates
Choosing Ovarian Preservation or Removal Before Surgery for Endometrial Cancer
NCT04569773
Recruiting
The purpose of this study is to learn more about the factors that influence decision-making before surgery (distress about cancer and/or reproductive concerns) and the possibility of regret after surgery.
Gender:
FEMALE
Ages:
Between 18 years and 50 years
Trial Updated:
05/13/2025
Locations: Hartford Healthcare (Data Collection), Hartford, Connecticut +7 locations
Conditions: Endometrial Cancer
Register for Updates
Technology Enabled Strategies to Promote Treatment Adherence in Liver Transplant
NCT05260268
Recruiting
Liver transplantation is increasingly performed for older adults with multiple comorbidities. Medication adherence is key to maintaining proper function of the transplanted liver and optimize health; however, adhering to post-transplant treatment is complex. This trial will study how available technology combined with transplant center resources and caregiver support can optimize medication adherence, quality of life, and health outcomes among new liver transplant recipients at 3 centers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: University of Miami, Miami, Florida +2 locations
Conditions: Liver Transplant; Complications, Cirrhosis, End Stage Liver DIsease, Medication Adherence
Register for Updates